Zongertinib in HER2-altered colorectal cancer: A pooled analysis of colorectal cancer patients from two clinical trials.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dirk Arnold, Noboru Yamamoto, Frans Opdam, Kiyotaka Yoh, Philippe Bedard, Jin Li, Erika Martinelli, John J. Park, Maria Garcia Pallas, Nick Pavlakis, Ana Gil, Behbood Sadrolhefazi, Daniel Martin Klotz, Lorenz Uhlmann, Gustavo Borghesi, Joanna Hussain, Anke Baum, Patrizia Sini, John V. Heymach, Alison M. Schram
Institutions: Asklepios Klinik Altona, Asklepios, National Cancer Center Hospital, The Netherlands Cancer Institute, National Cancer Center Hospital East, University Health Network, Princess Margaret Cancer Centre, China Pharmaceutical University, University of Campania "Luigi Vanvitelli", Macquarie University, GenesisCare, Hospital Universitario Virgen del Rocío, Boehringer Ingelheim (United States), Boehringer Ingelheim (Germany), Boehringer Ingelheim (United Kingdom), Boehringer Ingelheim (Austria), The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162541818
Cites:
Cited by:
Related to: